Showing results 10 to 16 of 16
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial Journal:The Lancet Gastroenterology & Hepatology | 2020 | ||
2021 | |||
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International | 2022 | ||
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology | 2019 | ||
2020 | |||
2008 | |||
Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial Journal:Annals of Internal Medicine | 2007 |